KOSDAQBiotech & Pharma100700

Sewoonmedical

₩2,165▲ 2.36%2026-11-18 close
Market Cap
₩94.8B
Turnover
₩100M
Volume
70K
Shares out.
43.8M
PER
7.9×
PBR
0.6×
EPS
₩277
Dividend Yield
3.21%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩70 per share · Prices as of the 2026-11-18 close

01

Report overview

Sales recover, but profits have fallen for four straight quarters

SEWOON MEDICAL's sales and operating profit rose year on year in the first half of 2026, but net profit attributable to controlling shareholders fell 60.0% year on year in the third quarter of 2026, extending a profit decline.

  1. 1

    Net profit attributable to controlling shareholders was KRW 11.9 billion in 2025, a second straight annual decline after the peak of KRW 15 billion in 2023.

  2. 2

    Third-quarter 2026 sales were KRW 15.3 billion and operating profit was KRW 2.39 billion, down 8.9% and 36.4% year on year.

  3. 3

    According to a WiseReport company summary, first-half 2026 consolidated sales rose 9.5% and operating profit rose 31.4%, so quarterly trends diverge.

  4. 4

    An average operating rate of 95% through September 2026 and a cost structure linked to the Vietnam subsidiary are cited as strengths.

  5. 5

    The 2026 annual report is the next scheduled checkpoint, and the direction of annual operating profit and net profit attributable to controlling shareholders is the key variable.

02

Business structure

SEWOON MEDICAL manufactures and sells disposable medical devices, including urological and drainage catheters and tubes, medical suction devices, infusion sets and stents. The company was founded in 1969 and listed on KOSDAQ in 2008.

A company summary puts medical devices at 99.7% of its business segment mix, so the business is effectively a single segment. In the third-quarter 2026 filing summary, infusion sets accounted for 16.0% of consolidated sales, stents 15.4%, and urological tubes and catheters 11.5%.

Its core suction devices and catheters were described in early-2010s press reports as substituting for imported products, with domestic share above 50%; those figures are older and may differ from today's share.

Its customer base centers on large domestic hospitals, and products are also exported to the United States, Japan, Europe and Taiwan. Production links the Cheonan plant with the Vietnam subsidiary to improve cost competitiveness, and the average operating rate for January to September 2026 was reported at 95%.

Competition with multinational device makers turns on price and quality. Unlike Samsung Biologics or Celltrion, which center on contract manufacturing or biologics, SEWOON MEDICAL is primarily a device maker, so its earnings drivers are cost, utilization and export growth.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩16.8B₩3.8B22.3%
2025Q4₩16.6B₩3.7B22.6%
2026Q1₩15.4B₩3.4B22.0%
2026Q2₩17.7B₩3.4B19.4%
2026Q3₩15.3B₩2.4B15.6%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩60.1B₩12.2B₩10.4B20.3%8.5%6.0%
2023₩68.2B₩16.9B₩15B24.8%11.1%6.5%
2024₩60.2B₩11.4B₩12.2B18.9%8.3%5.2%
2025₩63.7B₩12.7B₩11.9B20.0%7.9%6.1%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

Annual sales went from KRW 60.1 billion in 2022 to KRW 68.2 billion in 2023 (up 13.5%), then fell to KRW 60.2 billion in 2024 (down 11.9%) and rose to KRW 63.7 billion in 2025 (up 5.8%). 2023 was the largest year of 2022 to 2025 for sales, operating profit and net profit attributable to controlling shareholders.

Operating profit was KRW 12.2 billion in 2022, KRW 16.9 billion in 2023 (up 38.8%), KRW 11.4 billion in 2024 (down 32.8%) and KRW 12.7 billion in 2025 (up 11.6%). The operating margin was 20.3% in 2022, 24.8% in 2023, 18.9% in 2024 and 20.0% in 2025, so 2025 recovered from the 2024 level but stayed below the 2023 peak.

Net profit attributable to controlling shareholders rose from KRW 10.4 billion in 2022 to KRW 15 billion in 2023, then fell to KRW 12.2 billion in 2024 (down 18.7%) and KRW 11.9 billion in 2025 (down 2.1%), a second straight annual decline.

Net profit including non-controlling interests was KRW 12.2 billion in 2025 and is a separate figure from the attributable number. At the end of 2025, total equity was KRW 154.4 billion, of which KRW 151.2 billion was attributable to controlling shareholders, and total liabilities were KRW 9.47 billion.

The debt ratio was 6.1% in 2025. Operating cash flow peaked at KRW 23.1 billion in 2023, then was KRW 13.2 billion in 2024 and KRW 17.8 billion in 2025.

Quarterly, sales went from KRW 16.8 billion and operating profit of KRW 3.76 billion in the third quarter of 2025 to KRW 15.3 billion and KRW 2.39 billion in the third quarter of 2026, with net profit attributable to controlling shareholders down 60.0% year on year to KRW 1.48 billion.

Attributable net profit has declined for four consecutive quarters from the fourth quarter of 2025 through the third quarter of 2026, totaling KRW 11.7 billion over the last four quarters. Second-quarter 2026 sales of KRW 17.7 billion rose 15.1% from the prior quarter, so the decline has not been uninterrupted.

05

Industry analysis

Medical devices have been described as a segment supported by long-term demand from aging populations and rising chronic disease. Management said in the early 2010s that sales of medical supplies were rising as the number of older patients increased, though that statement is dated.

Replacing imported devices with domestic products has also been cited as a growth driver. A 2010 analysis noted that the company relies largely on imported silicone as its main raw material, so currency moves can affect input costs and profit.

Whether that cost structure still applies in 2026 can be checked in the cost lines of the annual report. In competition, SEWOON MEDICAL built its position on a customer base centered on large domestic hospitals and its existing product share.

Against multinational competitors, price competitiveness and product design suited to Korean body types have been presented as differentiators.

Peers in the same biopharma sector such as Alteogen, SK biopharmaceuticals and Hanmi Pharm are driven by drug development and clinical stages, whereas SEWOON MEDICAL's earnings track manufacturing indicators such as cost, utilization and export growth more closely.

06

Outlook

The most direct operating indicator confirmed is the production utilization rate, reported at an average of 95% for January to September 2026.

According to a WiseReport company summary, management is linking the Cheonan plant and the Vietnam subsidiary to improve profitability, pursuing growth through R&D and production efficiency, and focusing on expanding export markets.

The same summary put first-half 2026 consolidated sales up 9.5%, operating profit up 31.4% and net profit up 42.5%. Second-quarter 2026 sales rose 15.1% from the prior quarter, supporting the first-half improvement.

By contrast, third-quarter 2026 sales fell 8.9% year on year, and operating profit and net profit attributable to controlling shareholders fell 36.4% and 60.0%. Within the same year, the first-half improvement and the third-quarter slowdown point in different directions.

The next checkpoint is the 2026 annual report, covering full-year sales, operating profit and net profit attributable to controlling shareholders. The first-quarter 2027 report will show direction against first-quarter 2026 sales of KRW 15.4 billion and operating profit of KRW 3.38 billion.

07

Valuation

PER
7.9×
PBR
0.6×
ROE
7.7%
EPS
₩277
BPS
₩3,686
Dividend per share
₩70

The price-to-book ratio is below 1x, which means the shares trade at a discount to net asset value. Total equity at the end of 2025 was KRW 154.4 billion, of which KRW 151.2 billion was attributable to controlling shareholders, and the debt load is low.

Valuation discussion therefore splits between asset value and earnings power. On an earnings basis, the sum of net profit attributable to controlling shareholders over the most recent four quarters, KRW 11.7 billion, is the common reference.

Because third-quarter 2026 earnings fell, the multiple on those earnings rises at any given share price. Over several years, attributable net profit peaked in 2023 and then turned lower, while the first half of 2026 showed quarterly recovery signs.

As a KOSDAQ small-cap, the company is exposed to trading liquidity and price volatility. Dividend decisions will be confirmed with the 2026 annual report. How the multiple is read depends on whether earnings recover.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

First-half 2026 improvement

A WiseReport company summary put first-half 2026 consolidated sales up 9.5%, operating profit up 31.4% and net profit up 42.5% year on year. Second-quarter 2026 sales rose 15.1% from the prior quarter. Management attributes the gains to cost improvements at the Vietnam subsidiary and the Cheonan plant.

High production utilization

High utilization indicates that capacity is being absorbed by demand. Whether export expansion sustains this rate can be followed in later filings.

Low leverage and cash generation

The debt ratio at the end of 2025 was 6.1%, with total liabilities of KRW 9.47 billion against total equity of KRW 154.4 billion. Operating cash flow rose to KRW 17.8 billion in 2025 from KRW 13.2 billion in 2024. The balance sheet leaves limited financial strain even during the profit slowdown.

09

Bear factors

Sharp third-quarter 2026 profit drop

Third-quarter 2026 sales were KRW 15.3 billion, down 8.9% year on year, and operating profit was KRW 2.39 billion, down 36.4%. Net profit attributable to controlling shareholders was KRW 1.48 billion, down 60.0%. The four consecutive quarterly declines from the fourth quarter of 2025 form the core of the bearish case.

Two straight years of lower attributable profit

Net profit attributable to controlling shareholders fell from KRW 15 billion in 2023 to KRW 12.2 billion in 2024 and KRW 11.9 billion in 2025. The operating margin was 24.8% in 2023, 18.9% in 2024 and 20.0% in 2025, below the 2023 level. The 2025 decline narrowed to 2.1%, but the direction did not change.

Currency-linked inputs and domestic customer dependence

A 2010 analysis noted that silicone, the main input, is largely imported, so currency swings can affect costs. A customer base centered on large domestic hospitals may also be sensitive to hospital demand and policy changes. Both points come from older reporting, so current weights need confirmation in the annual report.

10

Risk factors

Inputs and currency

Heavy reliance on imported raw materials means exchange rates and input prices can directly affect costs and operating profit. The main analysis of this structure dates from 2010, so current cost composition needs confirmation in the annual report. If cost increases cannot be passed through to prices, the operating margin could narrow.

Customer concentration and hospital demand

Because the customer base centers on large domestic hospitals, changes in hospital purchasing policy or reimbursement rules could affect demand. Expanding exports is aimed at lowering this concentration, and changes in the overseas sales share can be tracked in quarterly reports.

Small-cap liquidity and volatility

With a market capitalization in the KOSDAQ small-cap range, trading volume and share price volatility can be large. During profit slowdowns, price moves can outpace changes in reported earnings. Thinly traded shares may see slower price discovery.

11

What to watch next

  1. Around March 31, 2027

    Filing of the 2026 annual report. The key checks are how full-year sales, operating profit and net profit attributable to controlling shareholders compare with the 2025 filed figures of KRW 63.7 billion, KRW 12.7 billion and KRW 11.9 billion, and whether the fourth-quarter trend continues the third-quarter decline.

  2. Around the regular shareholder meeting in March 2027

    Dividend decisions following the confirmation of 2026 annual results, and changes in total equity against KRW 154.4 billion at the end of 2025. Equity movement and payout decisions together show the company's capacity to return capital alongside its earnings trend.

  3. Around May 15, 2027

    The first-quarter 2027 quarterly report. Comparing against first-quarter 2026 sales of KRW 15.4 billion and operating profit of KRW 3.38 billion will show whether sales and operating profit are recovering and whether the decline since the third quarter of 2026 has stopped.

12

Overall view

SEWOON MEDICAL's sales rose from KRW 60.1 billion in 2022 to KRW 63.7 billion in 2025, but net profit attributable to controlling shareholders fell in 2024 and 2025 after peaking at KRW 15 billion in 2023. A WiseReport summary shows first-half 2026 sales and operating profit above the prior-year period.

However, third-quarter 2026 sales, operating profit and attributable net profit all fell year on year. Attributable net profit has declined for four consecutive quarters since the fourth quarter of 2025, totaling KRW 11.7 billion over the last four quarters.

Strengths include a 95% average operating rate through September 2026, low leverage and higher operating cash flow in 2025. Weaknesses include continued profit decline, sensitivity to imported inputs and currency, and dependence on large domestic hospitals.

The price-to-book ratio is below 1x, so asset value and the pace of earnings recovery frame the reading. The next checkpoints are the 2026 annual report and the first-quarter 2027 report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. comp.wisereport.co.kr
  2. jobkorea.co.kr
  3. tipranks.com
  4. edaily.co.kr
  5. oksiri.com
  6. edaily.co.kr
  7. investing.com
  8. comp.fnguide.com
  9. m.news.nate.com
  10. judal.co.kr
  11. jobkorea.co.kr
  12. etoday.co.kr
  13. betanews.net
  14. etoday.co.kr
  15. betanews.net
  16. saramin.co.kr
  17. etoday.co.kr
  18. etoday.co.kr

Report written 2026-11-13 · Data as of 2026-11-12

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis